Member Info for Uncanny

Oh, Porky is a non-holder too.

Strange that - the most active LSE posters don’t hold a share in VAL?

Rat, as a non-holder don’t you think that CLX and the new 201/CLX SPV will come good?

Answers on a postcard please….

Don’t they have two peptides for Prostate and Triple negative breast cancer?

Https://www.linkedin.com/posts/mark-eccleston-48382a_%F0%9D%90%8F%F0%9D%90%9E%F0%9D%90%A9%F0%9D%90%AD%F0%9D%90%A2%F0%9D%90%9D%F0%9D%90%9E%F0%9D%90%AC-%F0%9D%90%9A%F0%9D%90%AC-%F0%9D%90%93%F0%9D%90%A1%F0%9D%90%9E%F0%9D%90%AB%F0%9D%90%9A%F0%9D%90%A9%F0%9D%90%9E%F0%9D%90%AE%F0%9D%90%AD%F0%9D%90%A2%F0%9D%90%9C%F0%9D%90%AC-activity-7359203013086826496-ZgxU?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Https://research.open.ac.uk/innovation-engagement/knowledge-transfer-vouchers

Everything building nicely!

How many RNS’s now and new contracts to commence?

Of course waiting on 201 SPV and CLX update 👍

Well done ME.

Https://www.linkedin.com/posts/mark-eccleston-48382a_recent-nam-guidelines-provide-much-needed-activity-7356921970627600384-wR39?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Https://www.linkedin.com/posts/mark-eccleston-48382a_morris-animal-foundation-has-awarded-four-activity-7357004737507913728-qFt1?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Yes ME says they have "3 points of contact that they are discussing with".

Wow, well wouldn't that be a bomb shell when it is IND ready!

NAI DYOR!

You're a super start thank you!

And what was the reply Kuschall please if you can remember ?

Good find Patern - your research skills are second to none!

I wonder if AZN would be the natural home for CLX and a VAL deal?

Maybe if you persecutors, I present some personal monies to the roll Val at no premium over for 12 - 24 months potentially?

Keep the cat at bay.

Sorry Ray, the writings on the wall and sadly not in your direction of travel, but upwards!

Thanks Patern for this... I was not aware and you DYOR!

"A recent Val evaluation is with Omios Biologics (3/6/25), a California-based company specialising in virus immunotherapy. The alliance involves testing the synergetic ability of Cytolytix to enhance activity of the Omios platform and could potentially be used to target hemangiosarcoma in dogs – HSA causes the blood vessels to branch and become leaky, ultimately rupturing and is also highly metastatic, resulting in rapid spread to other organs. Mark already has history here, with Volition selling a dog tumour test for $26m. At what price a cure?"

My god you lot, probably find the nearest bridge, lol - don’t do that.

Everything falling into place now!

GLA DYOR NAI

The news I posted came out last night, LOL

Not desperate but just current news flow to share.

“ValiRx has multiple peptide programs- a 10 mer peptide targeting prostate cancer (Val201) and endometriosis (Val301) and a 15-mer Oncolytic peptide (Clx001).“

Mark Eccleston

“We believe peptides will be a cornerstone of tomorrow’s therapeutic landscape. With rapidly evolving enabling technologies in synthesis, stabilization, delivery, and manufacturing, they offer a versatile platform for designing next‑generation drugs: precise, effective, and scalable.”

“If you're in biopharma innovation and trying to modulate a new target perhaps now is the moment to dive into peptides.“

Ross Burn CEO CatSci